ABSTRACT
A great pitfall for scabies and pediculosis therapeutic studies to date is that primary and secondary study outcomes are indirectly assessed (presence or absence of live parasites, including eggs, determined by gross clinical inspection) and data are nonstandardized (highly variable) relative to time of therapeutic application. Certainly, kill times and kill rates are rarely determined or reported. Indeed, meta-analyses of randomized, controlled clinical trials for these parasitoses are scarce and, by nature, analyses are based on highly variable assessment methodology and data collection, followed by highly variable interpretation and reporting. 1 – 2
